# US 2023/0265531 A1 · Compositions and methods for one-step nucleic acid amplification and diagnostic methods based thereon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265531 A1
- Document ID: US20230265531A1
- Status: Published application
- Kind: A1
- Application number: 18/006,420
- Filed: 2021-07-22
- Published: 2023-08-24
- Earliest claimed: 2020-07-22
- Assignees: King Abdullah University of Science and Technology
- Applicants: King Abdullah University of Science and Technology
- Inventors: Samir M. Hamdan; Masateru Takahashi; Muhammad Tehseen; Etsuko Takahashi
- Web page: https://patentgrep.com/patent/US20230265531A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12Q 1/6851: Quantitative amplification
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Compositions and methods for a nucleic acid amplification and diagnostic methods based therein, are disclosed. The compositions include purified Thermus aquaticus DNA polymerase (Taq Pol) and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT), in proportions and under reaction conditions that allow one-step amplification of a nucleic acid of interest. In particular, the compositions are useful in one-step RT-qPCR and RT-LAMP methods. The method includes sampling the specimen from a subject, extracting and purifying RNA from the sample. The compositions and methods may be used to produce, analyze, quantitate, detect and otherwise manipulate nucleic acid molecules. For example, disclosed are methods of detecting the presence of a viral nucleic acid in a sample from a subject. Methods of diagnosing a subject as being infected with a viral pathogen are also provided. A preferred virus or pathogen is SARS-CoV-2.

## Claims

### Claim 1

An RT-PCR reagent composition comprising a Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) and a Thermus aquaticus DNA polymerase (Taq Pol) in effective amounts and in a buffer effective for one-step RT-PCR.

### Claim 2 (depends on 1)

The composition of claim 1 comprising MMLV-RT and Taq Pol in a 2:1 ratio.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the ratio comprises nanograms of MMLV-RT to units (U) of Taq Pol.

### Claim 4 (depends on 1)

The composition of claim 1 comprising from about 40 ng to about 80 ng MMLV-RT, from about 20 U to about 40 U Taq Pol, or combinations thereof.

### Claim 5 (depends on 4)

The composition of claim 4 comprising about 60 ng MMLV-RT and about 30 U Taq Pol.

### Claim 6 (depends on 1)

The composition of claim 1, wherein; (a) the MMLV-RT comprises the amino acid sequence of SEQ ID NO:1 or an amino acid sequence comprising at least 85% sequence identity to SEQ ID NO:1, (b) the Taq Pol comprises the amino acid sequence of SEQ ID NO:2 or an amino acid sequence comprising at least 85% sequence identity to SEQ ID NO:2; and/or (c) the MMLV-RT and/or Taq Pol further comprise one or more tag sequences at the N-terminus and/or C-terminus.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 8)

The composition of claim 8, where the tag sequence is selected from His tag and Strep tag.

### Claim 10 (depends on 1)

The composition claim 1, wherein the buffer comprises one or more of a salts a reducing agent, a chelating agent, a detergent a buffering agent, a plurality of deoxynucleoside triphosphates (dNTPs), or combinations thereof.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the one or more salts are selected from the group comprising KCl, MgCl2, and (NH4)2SO4.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the dNTPs are selected from the group consisting of dATP, dTTP, dGTP, and dCTP.

### Claim 13 (depends on 10)

The composition of claim 10 comprising 20-50 mM Tris-HCl (pH 8.5); 75-150 mM KCl; 2-4 mM MgCl2; 0.5-2 mM DTT; 200-500 μM dNTPs and 13.5 mM (NH4)2SO4.

### Claim 14 (depends on 1)

A method of performing a one-step RT-PCR comprising forming a mixture by combining an RNA sample/template and a plurality of primers with the composition of claim 1 and incubating the mixture under conditions sufficient to amplify one or more DNA molecules complementary to one or more portions of the RNA sample/template.

### Claim 15 (depends on 1)

A method of detecting presence of a nucleic acid in a sample comprising combining the sample and plurality of primers specific to the nucleic acid with the composition of claim 1 under conditions sufficient for amplification of the nucleic acid, and detecting the nucleic acid amplification product, thereby detecting presence of the nucleic acid in the sample.

### Claim 16 (depends on 15)

The method of claim 15, wherein the nucleic acid is derived from a coronavirus, preferably a severe acute respiratory syndrome-related coronavirus, more preferably SARS-CoV-2.

### Claim 17 (depends on 14)

The method of claim 14, wherein the sample is an RNA sample derived from mucus, sputum (processed or unprocessed), saliva, bronchial alveolar lavage (BAL), bronchial wash (BW), bodily fluids, cerebrospinal fluid (CSF), urine, tissue (e.g., biopsy material), rectal swab, nasopharyngeal aspirate, nasopharyngeal swab, throat swab, feces, plasma, serum, or whole blood.

### Claim 18 (depends on 15)

A method of diagnosing a subject for infection with a virus comprising detecting the presence of a viral nucleic acid in a sample from the subject by the method of claim 15, wherein detecting the amplification product indicates the subjects is infected with the virus.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject exhibits or does not exhibit symptoms of a disease, disorder, or condition associated with the virus, and/or the method further comprising treating the subject, wherein the subject was diagnosed as infected with the virus.

### Claim 20

(canceled)

### Claim 21 (depends on 18)

The method of claim 18, wherein the subject is human.

### Claim 22 (depends on 1)

The composition of claim 1 wherein the MMLV-RT sequence comprises a sequence represented by SSAG-A-L1-B-L2-C, where: (i) SSAG is an amino acid sequence or a variant thereof made by conservative substitution of the amino acids therein; (ii) A is a peptide cleave sequence, (iii) B is a protein tag as disclosed herein, (iv) L1 and L2 are optional first linkers, and (v) B is a second protein tag.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the MMLV-RT comprises SSAGENLYFQGSSSHHHHHHHHGGGSAWSHPQFEK (SEQ ID NO: 20).
